RxDoctor Payments Data

Antonio Alvarado, MD

Nephrology · New Braunfels, TXNPI 1497076988

Payments from drug & device makers

$78,275in general payments, 2019–2025

Across 380 payments — averaging $205.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$22K
  • Vifor Pharma, Inc.$19K
  • Otsuka America Pharmaceutical, Inc.$18K
  • AstraZeneca$13K
  • Akebia Therapeutics Inc$4K
  • Amgen$384
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$4,3506%
  • Speaking & faculty fees$54,86270%
  • Travel & lodging$11,76615%
  • Food & beverage$7,1599%
  • Education$1390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,275 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$386,154
Medicare patients
711
Services billed
5,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol142$158,794
VelphoroSucroferric Oxyhydroxide37$104,253
XphozahTenapanor Hcl24$74,361
JardianceEmpagliflozin40$53,313
MounjaroTirzepatide37$45,653
OzempicSemaglutide37$45,254
VeltassaPatiromer Calcium Sorbitex24$28,244
LokelmaSodium Zirconium Cyclosilicate12$20,307
Sevelamer Carbonate45$13,456
MyrbetriqMirabegron17$9,482
Calcium Acetate55$3,635
Bumetanide68$2,842
Hydralazine Hcl112$1,736
Nifedipine ErNifedipine90$1,617
Losartan Potassium177$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$13,306$179,101154 claims
Fresenius USA Marketing, Inc.Velphoro$79$104,25337 claims
Boehringer IngelheimJardiance$167$53,31340 claims
Lilly USA, LLCMounjaro$51$45,65337 claims
Novo NordiskOzempic$71$45,25437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.

Other nephrology in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →